This week in therapeutics

Indication	Target/marker/ pathway	Summary	Licensing status	Publication and contact information
Cancer				
Multiple myeloma (MM)	Serglycin (SRGN)	<i>In vitro</i> and mouse studies suggest inhibiting SRGN could help treat MM. In human MM cells, shRNA knockdown of SRGN inhibited adhesion to bone marrow stromal cells. In immunodeficient mice, tumor growth and vasculature development were decreased following subcutaneous injection of MM cells expressing SRGN shRNA compared with injection of cells expressing control shRNA. Next steps could include developing an SRGN inhibitor. SciBX 7(8); doi:10.1038/scibx.2014.223 Published online Feb. 27, 2014	Patent and licensing status unavailable	Purushothaman, A. & Toole, B.P. <i>J. Biol. Chem.</i> ; published online Jan. 8, 2014; doi:10.1074/jbc.M113.532143 Contact: Anurag Purushothaman, The University of Alabama at Birmingham, Birmingham, Ala. e-mail: anuragp@uab.edu